367 results about "Essential hypertension" patented technology

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

The invention discloses a medicine for treating hypertension. The medicine comprises Ligusticum wallichii, uncaria, Eucommia ulmoides, unprepared rehmannia root, Rhizoma Coptidis, Radix Scutellariae, Chinese angelica, Chinese Taxillus Twig, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, haw, Achyranthes bidentata, Radix Puerariae, Cortex Moutan, spine date seed, Semen Brassicae, Radix Astragali, prepared rehmannia root, white peony root, Tortoiseshell, Cortex Lycii, rhizoma gastrodiae, chrysanthemum, Spica Prunellae and Mythic Fungus according to a proper ratio. The medicine of the invention has curative effects on primary hypertension, renal hypertension and secondary hypertension, the effective rate of the medicine on hypertension is 100%, the cure rate is 98%, and the medicine which has the advantages of convenient oral administration, no toxic side effect, difficult recurrence after curing, fast effectiveness after the medicine administration and easily available and cheap medicinal material is an ideal medicine for treating above hypertension diseases.

The invention relates to a method for preparing Licardipine Hydrochloride slow-release agent, which can be used to treat hypertension, coronary disease or the like. The inventive slow-release agent is formed by quick-release stomach-soluble micro drop and slow-release enteric-soluble micro drop at 1:0.5-5 ratios in the hollow capsule. The inventive capsule has slow-release effect in 12 hours. The slow-release enteric-soluble micro drop comprises Licardipine Hydrochloride, medical macromolecule materials, drug release adjusting agent and some medical finding. The micro drops are prepared by extruding-rolling technique. The invention can quickly approach the blood drug density to treatment object and hold the density stably, with low side effect.

The invention discloses a novel orally-effective spirulina source antihypertensive peptide and a preparation method thereof. The antihypertensive peptide is a tripeptide with the sequence of isoleucine-glutamine-proline (Ile-Gln-Pro, IQP). An angiotensin converting enzyme (ACE) inhibitory peptide is prepared by the following steps of: performing enzymolysis on spirulina platensis by adopting alkali protease, and performing ultrafiltration, gel filtration chromatography and secondary reversed phase high-performance liquid chromatography purification. Tests prove that the IQP is a noncompetitive inhibitor of ACE, and can keep good ACE inhibitory activity under digestion of main gastrointestinal protease. The IQP has good antihypertensive effect on essential hypertension rat (SHR) and has great application prospects in medicaments and functional foods for preventing and treating hypertension.

An orally taken Chinese medicine for treating hypertension is prepared from prunella spike, uncaria stem with hooks, earthworm and cassia seed.

New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

An application of an invented medicinal composition in preparing the medicines for treating primary hypertension and protecting heart and kidney is disclosed.

The invention discloses a compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use. The inventive compound preparation is composed of following components by weight portion: 10-160 portion of timishatan, 0.5-50 protion of calcium antagonist. The calcium antagonist expands blood vessel to induce reflex sympathetic nerve excitement and the timishatan antagonizes neurohormone activity which is able to release from the sympathicus over-activation in the CCB blood pressure reduction, reduce the adverse effect induced by CCB treatment, provide all-around protection of the target organ such as heart, brain and kidney. The association of two acts synergistic effect to reduce blood pressure.

The invention discloses Chinese medicinal capsules for treating primitive high blood pressure of people in middle and old age, which are prepared from the following Chinese medicinal materials (by weight proportion): dried rehmannia root, prepared rhizome of rehmannia each 9.5-11.0%, fleece-flower root, mulberry seeds, ligustrum japonicum, flatstem milkvetch seed, puncturevine, cynomorium songaricum, achyranthes root, dodder seed, radish seeds, white atractylodes rhizome, wolfberry fruit 4.0-6.0%, plantain seeds, cassia seed each 6.5-7.0%, wild chrysanthemum flower, polygala root, acorus gramineus soland each 2.6-4.0%, asarum herb 0.2-2.0%.

An application of a high-intensity focused ultrasound system to treatment of essential hypertension. A treatment process includes: conducting ultrasonic positioning measurement on both sides of perirenal fat tissue of a patient, setting a therapeutic window and parameters of the system, and setting corresponding power parameter of the system, so as to make local temperature of the tissue during treatment reach 40-70° C., wherein treatment portions are both sides, and treatment scope is one third to all of the whole tissue; starting the system to treat one side of the tissue according to the set parameters and then the other. By treating a secondary center for regulating the activity of a whole-body sympathetic system, the activity of the whole-body sympathetic system can be reduced, so that the blood pressure level of the patient can be reduced, and fewer kinds and smaller dosage of antihypertensive drugs can be taken or ceased.

The invention belongs to the molecular biology and medicine field and relates to a method for detecting a susceptibility gene of hypertension and a detection kit thereof. The invention provides a method for detecting a susceptibility gene of essential hypertension, comprising the step of detecting the genetype of a mitochondrion fusion gene 2(Mfn2) / hyperplasia suppressor gene (HSG) locus rs7550536. The individual, rs7550536 of which carries the T genetype has obviously higher susceptibility of hypertension than the common people. The invention also discloses the corresponding detection kit which contains a primer amplifying the locus rs7550536 and a primer amplifying the region of the locus rs7550536 contained in the No.14 intron of the Mfn2 gene. Being used for detecting the genetype of the locus rs7550536, the method is simple and practicable, fast and efficient and low in cost and provides a simple and direct new way for hypertension diagnosis and treatment.

The invention discloses a levoamlodipine besylate liposome tablet and application thereof in the preparation of medicines for treating primary hypertension. The levoamlodipine besylate liposome tablet comprises the following components of levoamlodipine besylate, yolk lecithin, cholesterol, Poloxamer 188 and other medically used excipients according to the weight proportion ratio of 1 to (4-10) to (0.5-5) to (1-3) to (35-50). The liposome tablet greatly enhances the stability and the dissolution rate of the levoamlodipine besylate and has the advantages of less side effects, more remarkable curative effect, high utilization degree, less pollution, high economic value, and the like.

The invention belongs to the molecular biology and medicine field and relates to a method for detecting a susceptibility gene of hypertension and a detection kit thereof. The invention provides a method for detecting a susceptibility gene of essential hypertension, comprising the step of detecting the genetype of a mitochondrion fusion gene 2(Mfn2) / hyperplasia suppressor gene (HSG) locus rs2336384. The individual, rs2336384 of which carries the G genetype has obviously higher susceptibility of hypertension than the common people. The invention also discloses the corresponding detection kit which contains a primer amplifying the locus rs2336384 and a primer amplifying the region of the locus rs2336384 contained in the No.2 intron of the Mfn2 gene. Being used for detecting the genetype of the locus rs2336384, the method is simple and practicable, fast and efficient and low in cost and provides a simple and direct new way for hypertension diagnosis and treatment.

The invention relates to an enzymatic preparation method for antihypertensive peptides from jellyfish, which comprises: selecting fresh jellyfish or jellyfish processed with vitriol as raw materials, desalting, washing and grinding; regulating the protein concentration of jellyfish pulp to 1 to 3 percent; regulating pH value to 2 to 3.5, controlling the temperature to be 35 to 45 DEG C, adding pepsase, and keeping temperature to perform enzymolysis for 4 to 6 hours, wherein the added amount of the pepsase per gram of protein is 2,000 to 4,000um; regulating the pH value of the pepsase hydrolysate of jellyfish to 5 to 6, keeping the temperature between 50 and 55 DEG C, and adding papain to perform enzymolysis for 1 to 3 hours, wherein the added amount of papain per gram of protein is 2,000 to 4,000mu; and deactivating enzymes; and filtering with a membrane for removing impurities, desalinizing by a nanofiltration membrane, concentrating, spray-drying or freeze-drying to obtain powder of antihypertensive peptides from jellyfish. The antihypertensive peptides from jellyfish, which are prepared by the method, are proved in spontaneously hypertensive (SHR) rat oral taking experiments to have remarkable blood pressure reduction assisting effect. In the invention, the production process is advanced, the operability is high, the enzymolysis of the protein is complete, and the product quality is controllable.

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

The present invention includes compositions and methods for using a single pharmaceutical preparation of KMgCit is a convenient surrogate or to support the DASH diet in lowering blood pressure among patients with essential hypertension. Support is provided by potassium, magnesium and alkali, which overcome the underlying physiological-biochemical disturbances of essential hypertension, such as salt sensitivity, insulin resistance, low urinary pH, low serum magnesium and renal leak of calcium. Positive effects of KMgCitrate disclosed in normal subjects and patients with stones, provides assurance that KMgCitrate should ameliorate the above physiological-biochemical disturbances and associated disorders in patients with essential hypertension.

The invention belongs to the technical field of medicine, specifically discloses an optically sensitive pure S-(-)-arotinolol acid salt, and researches a preparation method and applications of the arotinolol acid salt at the same time. Through a large amount of research and experimental results, the technicians found that the prepared S-(-)-arotinolol acid salt is a crystal product, and can be used for preparation of drugs or heath care product for treating essential hypertension, angina pectoris, tachycardia induced arrhythmia, and essential tremor.

The invention discloses an angiotensin II receptor 1 type polypeptide-vector vaccine and an application thereof, belonging to the field of biotechnology drugs and biologic therapeutics. An angiotensin II receptor 1 type immunogenic peptide containing a first connection locus, a derivant thereof and one or more of carriers are preferably coupled and connected with recombined Qbeta-2aa bacteriophage viruslike particle protein to form an ordered and repeated polypeptide-carrier vaccine. The invention also discloses an application of the vaccine on the aspect of treating primary hypertension. Thevaccine can generate one section of efficient specific immunogenic peptide resisting human angiotensin II receptor 1 type and the antibody of the derivant thereof. RAS (Renin-Angiotensin System) can be effectively prevented from activating, the blood pressure of spontaneously hypertensive rats can be obviously lowered, and the vector vaccine has good function on protecting target organs.

The invention discloses a medicine compound containing candesartan cilexetil, and a preparation method thereof; and the medicine compound improves the stability of the base medicine and improves the dissolution rate of the medicine by preparing solid dispersion. The medicine compound is used for curing primary hypertension.

The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115 / 75 mm Hg or less throughout a 24 hour period. The current invention provides compositions comprising at least one hypertensive drug combined with the natural product Coenzyme Q10 (ubiquinone or CoQ10), which synergizes with the antihypertensive drugs to maintain low blood pressure throughout the day and night while generating other positive effects on the risks of cardiovascular disease, renal failure, and stroke. CoQ10 also counteracts some of the side effects of some hypertensive drugs such as tiredness, weakness, and / or liver toxicity. The invention further describes therapeutically effective methods for reducing systemic inflammation in hypertensive mammals comprising treatment with an antihypertensive composition that includes at least one angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and CoQ10 (ubiquinone). The invention metrics for reducing systemic inflammation comprise the reduction of serum levels of high sensitivity C-reactive protein (CRP), Interleukin 6 (IL-6), and / or tumor necrosis factor-alpha (TNF-alpha). These antihypertensive-CoQ10 combinations will synergistically reduce both hypertension and systemic inflammation.

An angiotensin IIreceptorI-type immune peptide section and its use are disclosed. The peptide section is selected from the amino-acid sequence as following: SEQ ID NO:181-187, amino-acid sequence of peptide section is Ala-Phe-His-Tyr-Glu-Ser-Arg; its analog is Ala-Phe-His-Tyr-Glu-Ser-Gln. It has excellent treatment performance, antigenicity and / or immunodominance. The use is carried out by feeding medicine by injecting for 0-8weeks. It can be used to treat primary hypertension as vaccine or medicinal composition.

The invention relates to an acrylamide compound with a structural formula I or an isomer thereof, a pharmaceutical salt thereof and a solvate thereof, and also relates to the compound or the isomer thereof or the pharmaceutical salt thereof and the solvate thereof, a composition of a pharmaceutically acceptable vector, an excipient or a diluent, and uses of the compound or the composition in preventing and / or treating diseases or symptoms which relate to cardiomyocyte apoptosis and include but are not limited to the uses of (i) treating hungry myocardial atrophy, (ii) treating myocarditis, (iii) treating cardiac failure, (iv) treating or relieving myocardial damage caused by essential hypertension, (v) treating or relieving myocardial damage caused by early-stage acute myocardial infarction, (vi) treating or relieving myocardial damage caused by acute myocardial infarction reperfusion, (vii) treating or relieving cardiomyocyte pathology caused by heart transplant, (viii) treating or relieving dysplastic cardiomyopathy, cardiomyocyte apoptosis caused by anoxia, or improving cardiovascular system sclerosis.

The present invention provides a recombinant glandular related virus capable of expressing human kallikrein, its preparation method and application, and medicine composition containing said recombinant glandular related virus. Said recombinant glandular related virus can drive the human kallikrein gene to make long-period expression in human body, and possesses good physiological and pathologic physiological action for effectively reducing blood pressure, improving renal function and preventing apoplexy, and can be used for clinical curing the above-mentioned diseases.

The invention relates to a method for extracting Yulang block to obtain Yulang water extractive, alcohol extractive, polysaccharide and chromocor. Researches have proved that the Yulang water extractive, alcohol extractive, polysaccharide and chromocor can stably reduce hypertension, restrain heart muscle retraction, reduce heart muscle oxygen consumption, improve coronary flux and reduce myocardial ischemia refill hurt, while it can release breath, release the asthma caused by acetylcholine simulation, and resist the retraction of acetylcholine or ergamine on bronchi. And the Yulang water extractive and polysaccharide can resist senile dementia and hepatitis or the like. The invention supplies a novel Chinese drug for treating hypertension, coronary disease, or the like, without side effect.

A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and / or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.

The invention discloses a hypotensor treating essential hypertension, which comprises the following material by weight percent: 10-20g tall gastrodia tuber, 10-20g gardenia, 15-25ml bamboo sap, 25-35g boiled sea-ear shell, 25-35g boiled nacre, 10-20g gambir plant, 10-15g eucommia bark, 10-20g taxillus twig, 10-15 baical skullcap root, 6-12g red paeony root, 15-25g dragon bones, 15-25g oyster shell, 15-25g agaric, 15-25g cinnabar root poria, 4-8g liquorice, 10-20g bamboo shavings, 10-15g Indian buead, 6-10g raw rhubarb, 6-10g safflower and 10-15g fetid cassia. The invention can tonify Qi, promote blood circulation, soften blood vessels, soothe heart and dredge meridian, therefore can complement kidney energy, improve heart power, extend blood vessels and the like. The invention can eliminate headache, insomnia and heart-throb and completely cure hypertension and avoid recidivation.

This invention relates to methods for detecting the deficiency of magnesium tightly bound to cellular membranes, i.e., magnesium binding defect, which deficiency is associated with certain abnormal physiological states, e.g., salt-sensitive essential hypertension or Type 2 diabetes mellitus.